Moorestown-based Tabula Rasa HealthCare Inc., a health care technology company, announced it has agreed to acquire Brisbane, Australia-based DoseMe.
DoseMe is the developer of DoseMeRx, a precision dosing tool for physicians and pharmacists.
Under terms of the deal, DoseMeRx will be combined with TRHC’s proprietary Medication Risk Mitigation technologies to enhance medication safety solutions in hospitals.
“With DoseMe’s state-of-the-art decision support tool combined with our ability to predict and prevent harmful drug interactions through tools such as the MRM Matrix, we are now able to offer hospitals a broader range of protection against adverse drug events, the fourth leading cause of death in the US,” TRHC Chairman and CEO Calvin H. Knowlton said. “Together, we can power the shift to precision prescribing, tailoring medication to meet individual needs and tolerances, which will have a profound impact on safety, quality, and costs, such as medication-related increased hospital length-of-stay.”
The acquisition is expected to close in the first quarter of 2019. Following the close of the deal, DoseMe will become part of TRHC’s CareVention HealthCare technology and service division.
“By joining Tabula Rasa HealthCare, we are able to more effectively combat the growing problem of adverse drug events, most of which can be prevented through better medication monitoring and dosing,” DoseMe CEO Charles Cornish said. “We look forward to working with TRHC to provide clinicians with the tools they need to optimize medication therapy and improve patients’ quality of life.”
Morgan, Lewis & Bockius LLP served as legal counsel to TRHC. Faegre Baker Daniels LLP served as legal counsel to DoseMe. Match Point Partners served as the financial advisor to DoseMe.
